A Phase I-IIa Study of Safety, Tolerance, Pharmacokinetics, Dosimetry and Benefice of Early Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis
Phase of Trial: Phase I/II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Tc-99m annexin V 128 (Primary)
- Indications Ankylosing spondylitis; Rheumatoid arthritis
- Focus Adverse reactions; Diagnostic use
- Sponsors Advanced Accelerator Applications
- 26 Oct 2017 Status changed from recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 23 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.